Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabidiol as a potential treatment for psychosis
Cathy Davies, Sagnik Bhattacharyya
Therapeutic Advances in Psychopharmacology (2019) Vol. 9
Open Access | Times Cited: 98

Showing 26-50 of 98 citing articles:

The Development of Cannabinoids as Therapeutic Agents in the United States
Conor H. Murray, Brenda M. Gannon, Peter J. Winsauer, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 5, pp. 915-955
Open Access | Times Cited: 3
The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the Differential Effects of Δ9-Tetrahydrocannabinol and Cannabidiol
Brandon Gunasekera, Cathy Davies, Rocı́o Martı́n-Santos, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2020) Vol. 6, Iss. 6, pp. 636-645
Closed Access | Times Cited: 26
Endocannabinoid-serotonin systems interaction in health and disease
Roberto Colangeli, G. Campbell Teskey, Giuseppe Di Giovanni
Progress in brain research (2021), pp. 83-134
Closed Access | Times Cited: 23
Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats
Marina Gabaglio, Erica Zamberletti, Cristina Manenti, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8899-8899
Open Access | Times Cited: 22
Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study
Lucy Ma, Sofia Platnick, Howard Platnick
Cureus (2022)
Open Access | Times Cited: 14
Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum
João Francisco Cordeiro Pedrazzi, Amanda J. Sales, Francisco Silveira Guimarães, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2021) Vol. 111, pp. 110352-110352
Open Access | Times Cited: 19
A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders
Maria Athanassiou, Alexandre Dumais, Gismonde Gnanhoue, et al.
Expert Review of Neurotherapeutics (2021) Vol. 21, Iss. 7, pp. 779-791
Open Access | Times Cited: 18
Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice
Aymen H. Sadaka, Ana G. Ozuna, Richard J. Ortiz, et al.
Journal of Translational Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 17
Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
Laísa S. Umpierrez, Priscila A. Costa, Eden A. Michelutti, et al.
Psychopharmacology (2022) Vol. 239, Iss. 5, pp. 1593-1603
Open Access | Times Cited: 12
Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia
Ammara Saleem, Qurat-ul-Ain Qurat-ul-Ain, Muhammad Furqan Akhtar
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Cannabis consumption and prosociality
Jacob M. Vigil, Sarah S. Stith, Tiphanie Chanel
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis Compounds
Anna Rybarczyk, Aleksandra Majchrzak‐Celińska, Violetta Krajka‐Kuźniak
Antioxidants (2023) Vol. 12, Iss. 12, pp. 2052-2052
Open Access | Times Cited: 6
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies
Laura Fusar‐Poli, Vito Cavone, Silvia Tinacci, et al.
(2020)
Open Access | Times Cited: 15
A Mini-Review of Relationships Between Cannabis Use and Neural Foundations of Reward Processing, Inhibitory Control and Working Memory
Kristen P. Morie, Marc N. Potenza
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 14
Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
Cathy Davies, Elizabeth Appiah‐Kusi, Robin Wilson, et al.
European Archives of Psychiatry and Clinical Neuroscience (2021) Vol. 272, Iss. 3, pp. 461-475
Open Access | Times Cited: 14
The clinical and functional outcomes of a large naturalistic cohort of young people accessing national early psychosis services
Ellie Brown, Caroline X. Gao, Heather Staveley, et al.
Australian & New Zealand Journal of Psychiatry (2021) Vol. 56, Iss. 10, pp. 1265-1276
Closed Access | Times Cited: 13
Effects of Cannabidiol Interactions with CYP2R1, CYP27B1, CYP24A1, and Vitamin D3 Receptors on Spatial Memory, Pain, Inflammation, and Aging in Vitamin D3 Deficiency Diet-Induced Rats
Mahendra Kumar Trivedi, Sambhu Charan Mondal, Mayank Gangwar, et al.
Cannabis and Cannabinoid Research (2022) Vol. 8, Iss. 6, pp. 1019-1029
Closed Access | Times Cited: 8
Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis
Brandon Gunasekera, Robin Wilson, Aisling O’Neill, et al.
Psychological Medicine (2022) Vol. 53, Iss. 10, pp. 4732-4741
Closed Access | Times Cited: 8
A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.
Rachel Little, Dale A. D’Mello
PubMed (2022) Vol. 19, Iss. 7-9, pp. 38-43
Closed Access | Times Cited: 8
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Francesco Bartoli, Ilaria Riboldi, Bianca Bachi, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 6, pp. 1303-1303
Open Access | Times Cited: 11
Cannabidiol enhances cerebral glucose utilization and ameliorates psychopathology and cognition: A case report in a clinically high-risk mental state
Dagmar Koethe, Cathrin Rohleder, Lutz Kracht, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 4
Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk
Cathy Davies, Matthijs G. Bossong, Daniel Martins, et al.
Schizophrenia Bulletin Open (2023) Vol. 4, Iss. 1
Open Access | Times Cited: 4
Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol
Cathy Davies, Matthijs G. Bossong, Daniel Martins, et al.
Psychological Medicine (2023) Vol. 54, Iss. 5, pp. 993-1003
Open Access | Times Cited: 4
Psychosis in Parkinson’s Disease: Looking Beyond Dopaminergic Treatments
Milagros Rojas, Mervin Chávez-Castillo, Pablo Durán, et al.
Current Pharmaceutical Design (2022) Vol. 28, Iss. 33, pp. 2725-2741
Closed Access | Times Cited: 7
Cannabis use‐related working memory deficit mediated by lower left hippocampal volume
Subhadip Paul, Sagnik Bhattacharyya
Addiction Biology (2020) Vol. 26, Iss. 4
Closed Access | Times Cited: 10

Scroll to top